Intersurgical, a leading global manufacturer of medical devices, announces its strategic expansion within Lithuania, with a proposed €10 million investment aimed at enhancing its manufacturing capabilities by the end of 2024. Celebrating three decades of operations in the country, the company is set to augment its presence in Pabradė through the establishment of a new, state-of-the-art manufacturing facility and the procurement of advanced equipment.
The project's initial phase is already underway, with plans to construct a 2,500 square meter production site equipped with high-tech automated production lines adjacent to the current 80,000 square meter factory in Pabradė by December 2024. This initial investment will be followed by an additional infusion of approximately €18 million over the subsequent three to four years, aimed at further expanding the company’s innovative product range and enhancing its market reach. Lithuanian-made products by Intersurgical are currently reaching diverse global markets, including the US, Germany, the UK, France, Japan, and Australia.
Highlighting the significance of this development, the Minister of Economy and Innovation, Aušrinė Armonaitė, and Elijus Čivilis, General Manager of Invest Lithuania, lauded Intersurgical’s role in invigorating Lithuania’s regions through advanced industrial growth. They noted the company's contribution to the local economy through innovation, research, and a high level of expertise, which has fostered the development and optimization of production processes within Lithuania.
Mr. Žvirblis, CEO of Intersurgical Lithuania, emphasized the company’s commitment to technological advancement and employee skill enhancement. "Our investment in cutting-edge technology necessitates extensive training for our team. Annually, we conduct thousands of training sessions and collaborate with vocational schools to ensure our staff is proficient with new technologies, which is vital for the seamless operation of our new production lines," he stated.
Intersurgical’s Lithuanian operations, with approximately 2,200 employees across the Visaginas and Pabradė sites, represent over half of the company's global workforce. With 28 subsidiaries and 6 manufacturing sites worldwide, the Lithuanian branch is a critical hub, contributing significantly to the group's overall production output. The company specializes in a wide array of medical products, including those for resuscitation and intensive care, anaesthesia, oxygen and aerosol therapy, and airway management, reinforcing its position as a pioneer in the medical device industry.
